Neisseria Lactamica Protects Against Experimental Meningococcal Infection

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 2002 Jun 18

PMID 12065503

Citations 29

Authors

Kerry J Oliver

Karen M Reddin

Philippa Bracegirdle

Michael J Hudson

Ray Borrow

Ian M Feavers

Andrew Robinson

Keith Cartwright

Andrew R Gorringe

Affiliations

Soon will be listed here.

Abstract

Immunological and epidemiological evidence suggests that the development of natural immunity to meningococcal disease results from colonization of the nasopharynx by commensal Neisseria spp., particularly with N. lactamica. We report here that immunization with N. lactamica killed whole cells, outer membrane vesicles, or outer membrane protein (OMP) pools and protected mice against lethal challenge by a number of diverse serogroup B and C meningococcal isolates in a model of bacteremic infection. Sera raised to N. lactamica killed whole cells, OMPs, or protein pools were found to cross-react with meningococcal isolates of a diverse range of genotypes and phenotypes. The results confirm the potential of N. lactamica to form the basis of a vaccine against meningococcal disease.

Citing Articles

Peptidoglycan fragment release and NOD activation by commensal species from humans and other animals.

Harris-Jones T, Chan J, Hackett K, Weyand N, Schaub R, Dillard J Infect Immun. 2024; 92(5):e0000424.

PMID: 38563734 PMC: 11075463. DOI: 10.1128/iai.00004-24.

Effect of colonisation with Neisseria lactamica on cross-reactive anti-meningococcal B-cell responses: a randomised, controlled, human infection trial.

Dale A, Theodosiou A, Gbesemete D, Guy J, Jones E, Hill A Lancet Microbe. 2022; 3(12):e931-e943.

PMID: 36462524 PMC: 7615047. DOI: 10.1016/S2666-5247(22)00283-X.

Antimicrobial susceptibility of commensal Neisseria in a general population and men who have sex with men in Belgium.

Laumen J, Van Dijck C, Abdellati S, De Baetselier I, Serrano G, Manoharan-Basil S Sci Rep. 2022; 12(1):9.

PMID: 34997050 PMC: 8741786. DOI: 10.1038/s41598-021-03995-1.

Deletion of major porins from meningococcal outer membrane vesicle vaccines enhances reactivity against heterologous serogroup B Neisseria meningitidis strains.

Matthias K, Reveille A, Connolly K, Jerse A, Gao Y, Bash M Vaccine. 2020; 38(10):2396-2405.

PMID: 32037226 PMC: 11656520. DOI: 10.1016/j.vaccine.2020.01.038.

Variant Signal Peptides of Vaccine Antigen, FHbp, Impair Processing Affecting Surface Localization and Antibody-Mediated Killing in Most Meningococcal Isolates.

da Silva R, Karlyshev A, Oldfield N, Wooldridge K, Bayliss C, Ryan A Front Microbiol. 2020; 10:2847.

PMID: 31921030 PMC: 6930937. DOI: 10.3389/fmicb.2019.02847.

References

Lehmann A, Gorringe A, Reddin K, West K, Smith I, Halstensen A . Human opsonins induced during meningococcal disease recognize transferrin binding protein complexes. Infect Immun. 1999; 67(12):6526-32. PMC: 97063. DOI: 10.1128/IAI.67.12.6526-6532.1999. View

Troncoso G, Sanchez S, Moreda M, Criado M, Ferreiros C . Antigenic cross-reactivity between outer membrane proteins of Neisseria meningitidis and commensal Neisseria species. FEMS Immunol Med Microbiol. 2000; 27(2):103-9. DOI: 10.1111/j.1574-695X.2000.tb01419.x. View

Coen P, Cartwright K, Stuart J . Mathematical modelling of infection and disease due to Neisseria meningitidis and Neisseria lactamica. Int J Epidemiol. 2000; 29(1):180-8. DOI: 10.1093/ije/29.1.180. View

Borrow R, Andrews N, Goldblatt D, Miller E . Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun. 2001; 69(3):1568-73. PMC: 98057. DOI: 10.1128/IAI.69.3.1568-1573.2001. View

Kim J, Mandrell R, Griffiss J . Neisseria lactamica and Neisseria meningitidis share lipooligosaccharide epitopes but lack common capsular and class 1, 2, and 3 protein epitopes. Infect Immun. 1989; 57(2):602-8. PMC: 313139. DOI: 10.1128/iai.57.2.602-608.1989. View

Goldschneider I, Gotschlich E, Artenstein M . Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969; 129(6):1307-26. PMC: 2138650. DOI: 10.1084/jem.129.6.1307. View

Olsen S, Djurhuus B, Rasmussen K, JOENSEN H, Larsen S, Zoffman H . Pharyngeal carriage of Neisseria meningitidis and Neisseria lactamica in households with infants within areas with high and low incidences of meningococcal disease. Epidemiol Infect. 1991; 106(3):445-57. PMC: 2271871. DOI: 10.1017/s0950268800067492. View

Gu X, Tsai C . Purification of rough-type lipopolysaccharides of Neisseria meningitidis from cells and outer membrane vesicles in spent media. Anal Biochem. 1991; 196(2):311-8. DOI: 10.1016/0003-2697(91)90472-6. View

Wilson H, Overman T . Septicemia due to Neisseria lactamica. J Clin Microbiol. 1976; 4(3):214-5. PMC: 274438. DOI: 10.1128/jcm.4.3.214-215.1976. View

10.

Gold R, Goldschneider I, LEPOW M, Draper T, Randolph M . Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis. 1978; 137(2):112-21. DOI: 10.1093/infdis/137.2.112. View

11.

Maiden M, Spratt B . Meningococcal conjugate vaccines: new opportunities and new challenges. Lancet. 1999; 354(9179):615-6. DOI: 10.1016/s0140-6736(99)00252-4. View

12.

Abdillahi H, Poolman J . Typing of group-B Neisseria meningitidis with monoclonal antibodies in the whole-cell ELISA. J Med Microbiol. 1988; 26(3):177-80. View

13.

Vogel U, Claus H, Frosch M . Rapid serogroup switching in Neisseria meningitidis. N Engl J Med. 2000; 342(3):219-20. DOI: 10.1056/NEJM200001203420319. View

14.

Cartwright K, Stuart J, Noah N . An outbreak of meningococcal disease in Gloucestershire. Lancet. 1986; 2(8506):558-61. DOI: 10.1016/s0140-6736(86)90124-8. View

15.

Cann K, Rogers T . Detection of antibodies to common antigens of pathogenic and commensal Neisseria species. J Med Microbiol. 1989; 30(1):23-31. DOI: 10.1099/00222615-30-1-23. View

16.

Zorgani A, James V, Stewart J, Blackwell C, Elton R, WEIR D . Serum bactericidal activity in a secondary school population following an outbreak of meningococcal disease: effects of carriage and secretor status. FEMS Immunol Med Microbiol. 1996; 14(2-3):73-81. DOI: 10.1111/j.1574-695X.1996.tb00273.x. View

17.

Miller E, Salisbury D, Ramsay M . Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine. 2001; 20 Suppl 1:S58-67. DOI: 10.1016/s0264-410x(01)00299-7. View

18.

Martin S, Borrow R, van der Ley P, Dawson M, Fox A, Cartwright K . Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine. 2000; 18(23):2476-81. DOI: 10.1016/s0264-410x(00)00047-5. View

19.

West D, Reddin K, Matheson M, Heath R, Funnell S, Hudson M . Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infect Immun. 2001; 69(3):1561-7. PMC: 98056. DOI: 10.1128/IAI.69.3.1561-1567.2001. View

20.

Jones D, Mallard R . Age incidence of meningococcal infection England and Wales, 1984-1991. J Infect. 1993; 27(1):83-8. DOI: 10.1016/0163-4453(93)93978-d. View